- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Endo Aesthetics Announces FDA Approval of QWO for Cellulite Treatment
Author(s):
Endo Aesthetics announced the U.S. FDA approval of QWO for the first and only injectable treatment of moderate to severe cellulite of the buttocks in adult women.
Endo Aesthetics recently announced the U.S. FDA approval of collagenase clostridium histolyticum-aaes (QWO) for the treatment of moderate to severe cellulite in the buttocks of adult women.
A primary contributing factor to cellulite is the fibrous septae, which connect the skin perpendicularly to the facia underneath. The fibrous septae tether to the skin, drawing it downwards and cause dimpling.
Through injection, QWO is thought to release these tethers enzymatically, specifically targeting Types one and three of collagen. This results in skin smoothing and an improved appearance of cellulite post treatment, according to the press release.
“Endo recognized a significant unmet need for an effective and non-invasive injectable treatment for cellulite, which led us to conduct the largest clinical trials in the history of cellulite investigation in the United States,” says Matthew Davis, MD, RPh, senior vice president and chief medical officer of Endo, in the release. “Supported by rigorous research, testing and development processes, we are proud to have received FDA approval of the first injectable treatment for cellulite in the buttocks and we look forward to delivering QWO to the aesthetics community and their adult female patients.”
Potential adverse events include injection site bruising, pain, areas of hardness, redness, discoloration, swelling, localized warmth, and itching in the treatment area.
QWO is the first FDA-approved cellulite injectable treatment and is expected to be available in practices throughout the United States starting in spring 2021, according to Endo.
“QWO could be a game-changer for many women with cellulite,” says Anne Chapas, MD, a board-certified dermatologist at Union Square Laser Dermatology in New York City, in the release. “I am thrilled there will now be an FDA-approved injectable treatment option proven to address a root cause of cellulite. What is exciting about QWO is that it is a cutting-edge cellulite treatment, without the cutting.”
